Absci Corporation.(ABSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABSI Absci Corporation.

Trading 05-12 11:10:39 EDT

5.58

-0.20

-3.55%

High5.74	Low5.46	Vol1.28M
Open5.70	D1 Closing5.78	Amplitude4.84%
Mkt Cap866.62M	Tradable Cap813.95M	Total Shares155.45M
T/O7.18M	T/O Rate0.88%	Tradable Shares146.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABSI","market":"US","secType":"STK","nameCN":"Absci Corporation.","latestPrice":5.575,"timestamp":1778598637009,"preClose":5.78,"halted":0,"volume":1278524,"delay":0,"changeRate":-0.03546712802768167,"floatShares":146000000,"shares":155447428,"eps":-0.823032,"marketStatus":"Trading","change":-0.205,"latestTime":"05-12 11:10:39 EDT","open":5.702,"high":5.74,"low":5.4602,"amount":7178666.2719824,"amplitude":0.048408,"askPrice":5.58,"askSize":200,"bidPrice":5.57,"bidSize":441,"shortable":3,"etf":0,"ttmEps":-0.823032,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778616000000},"marketStatusCode":2,"adr":0,"listingDate":1626926400000,"exchange":"NASDAQ","adjPreClose":5.78,"preHourTrading":{"tag":"盘前","latestPrice":5.71,"preClose":5.78,"latestTime":"09:29 EDT","volume":17788,"amount":103056.049842,"timestamp":1778592599999,"change":-0.07,"changeRate":-0.012111,"amplitude":0.050173},"postHourTrading":{"tag":"盘后","latestPrice":5.82,"preClose":5.78,"latestTime":"19:57 EDT","volume":44420,"amount":257622.8169,"timestamp":1778543860798,"change":0.04,"changeRate":0.00692,"amplitude":0.013754},"volumeRatio":0.756986,"impliedVol":1.3952,"impliedVolPercentile":0.8526},"requestUrl":"/m/hq/s/ABSI/wiki","defaultTab":"wiki","newsList":[{"id":"2634228619","title":"Guggenheim Remains a Buy on AbSci (ABSI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634228619","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634228619?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:53","pubTimestamp":1778500438,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from Guggenheim reiterated a Buy rating on AbSci, with a price target of $10.00. In a report released today, H.C. W...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-absci-absi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-absci-absi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4121","ABSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634002754","title":"H.C. Wainwright Remains a Buy on AbSci (ABSI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634002754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634002754?lang=en_us&edition=fundamental","pubTime":"2026-05-11 18:39","pubTimestamp":1778495968,"startTime":"0","endTime":"0","summary":"In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on AbSci, with a price target of $8.00. Ramakanth c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-absci-absi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-absci-absi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABSI","BK4539","BK4139","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634465340","title":"Absci’s ABS-201 Hair-Loss Trial Moves Forward: What Early-Stage Data Could Mean for ABSI","url":"https://stock-news.laohu8.com/highlight/detail?id=2634465340","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634465340?lang=en_us&edition=fundamental","pubTime":"2026-05-09 00:33","pubTimestamp":1778258028,"startTime":"0","endTime":"0","summary":"Absci Corp. ($ABSI) announced an update on their ongoing clinical study. Absci Corp. (ABSI) has launched a first-in-human trial titled “A Randomize...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abscis-abs-201-hair-loss-trial-moves-forward-what-early-stage-data-could-mean-for-absi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abscis-abs-201-hair-loss-trial-moves-forward-what-early-stage-data-could-mean-for-absi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","BK4139","BK4539","BK4121","ABSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634463318","title":"Absci Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2634463318","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634463318?lang=en_us&edition=fundamental","pubTime":"2026-05-09 00:04","pubTimestamp":1778256240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABSI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 12:04 ET (16:04 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4139","ABSI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633457229","title":"Absci Shares Fall After 1Q Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2633457229","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633457229?lang=en_us&edition=fundamental","pubTime":"2026-05-08 22:40","pubTimestamp":1778251200,"startTime":"0","endTime":"0","summary":"Shares of Absci were lower after the company's losses widened and its revenue fell in its latest quarter.Shares of the artificial intelligence-driven drug creation company were down 3% on Friday at $5.59. The company's shares are up 58% year to date.The company on Thursday posted a first-quarter loss of $29.6 million, or 19 cents a share, compared with a loss of $26.3 million, or 21 cents a share, a year earlier. Analysts polled by FactSet had expected a loss of 20 cents a share.Revenue fell to $215,000 from $1.2 million a year earlier. Analysts had expected $1.4 million.The company's research and development expenses rose to $19.3 million from $16.4 million in the year-earlier quarter.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABSI","BK4121","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633177392","title":"Absci Q1 revenue drops, misses estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633177392","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633177392?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:55","pubTimestamp":1778187315,"startTime":"0","endTime":"0","summary":"Absci Q1 revenue drops, misses estimatesOverviewUS biopharmaceutical firm's Q1 revenue fell sharply and missed analyst expectationsNet loss widened yr/yr, driven by higher R&D expenses for internal pr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K1K2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABSI","BK4539","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633179966","title":"Absci Q1 EPS $(0.19) Beats $(0.23) Estimate, Sales $215.000K Miss $1.550M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633179966","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633179966?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:11","pubTimestamp":1778184670,"startTime":"0","endTime":"0","summary":"Absci (NASDAQ:ABSI) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 9.52 percent increase over losses of $(0.21) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52388475/absci-q1-eps-0-19-beats-0-23-estimate-sales-215-000k-miss-1-550m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Absci Q1 EPS $(0.19) Beats $(0.23) Estimate, Sales $215.000K Miss $1.550M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4121","ABSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633217985","title":"BRIEF-Absci Q1 Pretax Profit USD -29.581 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633217985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633217985?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:05","pubTimestamp":1778184346,"startTime":"0","endTime":"0","summary":"BRIEF-Absci Q1 Pretax Profit USD -29.581 Million\n\n\nMay 07 (Reuters) - Absci Q1 operating income USD -30.846 million.\n\nQ1 operating expenses USD 31.061 million\nQ1 net income USD -29.599 million\nQ1 basic EPS USD -0.19\nQ1 revenue USD 215 thousand vs. IBES estimate USD 1.55 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX7935CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABSI","BK4539","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633612753","title":"Absci publishes corporate presentation on generative AI drug creation platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2633612753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633612753?lang=en_us&edition=fundamental","pubTime":"2026-05-08 01:22","pubTimestamp":1778174530,"startTime":"0","endTime":"0","summary":"Absci outlined strategy built around generative AI with an integrated, automated 77,000-square-foot wet lab aimed at shortening antibody discovery cycles to about six weeks.Lead program ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia, remains on track for an accelerated Phase 1/2a study with interim proof-of-concept data expected in 2H 2026.Program expansion into endometriosis targets Phase 2 start in 4Q 2026 with proof-of-concept data as early as 2H 2027.Absci highlighted ABS-101 for inflammatory bowel disease as ready for partnering, citing improved half-life and tissue penetration versus first-generation TL1a molecules.Presentation framed platform economics as about $10 million to $15 million and roughly 24 months to reach candidates, versus $50 million to $100 million and 5 to 6 years for large pharma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL491hC4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ABSI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633117886","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2633117886","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633117886?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:00","pubTimestamp":1778148000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Ares Comm. RE                                   1Q       .07    6:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASC","ACMR","AMN","APPN","ARW","ACLS","ANAB","ABNB","ARTV","AMLX","AORT","AVPT","ATLC","AVNT","AFCG","ALTG","AMPH","ARWR","AKAM","ALGM","AFRM","BBDC","APYX","AAOI","ARCT","ARHS","ASPN","ASMB","AMTX","DDOG","BKV","ALRM","ACIW","BBIO","ASTH","ATHM","AAON","ARLO","AURA","ALT","ASND","ABX","AKBA","AMPX","ARGX","ABSI","ACHR","ACRE","AHR","AGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633921639","title":"Absci Corp  expected to post a loss of 21 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633921639","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633921639?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:28","pubTimestamp":1778012885,"startTime":"0","endTime":"0","summary":"Absci Corp  expected to post a loss of21cents a share - Earnings Preview Absci Corp ABSI.OQ ABSI.O is expected to  show a rise in quarterly revenue when it reports  results on May 7 for the period end","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL8N41I38X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4539","ABSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633015967","title":"Absci grants 276,200-share stock option at $4.92 under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2633015967","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633015967?lang=en_us&edition=fundamental","pubTime":"2026-05-05 08:11","pubTimestamp":1777939912,"startTime":"0","endTime":"0","summary":"Absci granted a non-statutory stock option for 276,200 common shares to one newly hired non-executive employee on May 1, 2026.Exercise price set at USD 4.92 per share; option term 10 years.Vesting set over four years, with 25% vesting on first anniversary of grant date; remaining 75% vesting in 36 roughly equal monthly installments.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL2Fq0P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","ABSI","SG9999014021.USD","BK4585","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","BK4588","LU2210150020.SGD","BK4539","LU0314104364.USD","NDAQ","SG9999014039.USD","BK4139","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633670189","title":"Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633670189","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633670189?lang=en_us&edition=fundamental","pubTime":"2026-05-05 08:11","pubTimestamp":1777939901,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nTUAD49TB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4121","ABSI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630731520","title":"BUZZ-Absci rises as brokerage highlights growing opportunity in hair‑loss market","url":"https://stock-news.laohu8.com/highlight/detail?id=2630731520","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630731520?lang=en_us&edition=fundamental","pubTime":"2026-04-28 00:15","pubTimestamp":1777306525,"startTime":"0","endTime":"0","summary":"BUZZ-Absci rises as brokerage highlights growing opportunity in hairloss market** Shares of AI-based drug developer Absci Corp ABSI.O rise 15.2% to $4.54 in early trading** Brokerage KeyBanc says positive mid-to-late stage data from rival Veradermics MANE.N for its oral hair-loss pill reinforce the view that the hair-loss market is sizable and can support multiple therapies** Estimates a more than $40 bln market opportunity for hair-loss treatments and reiterates a $9 price target on Absci** Shares of peer biotech firm Veradermics jump 37.3% to $93.72, Nektar up ~1% to $92.17** Brokerage says Absci's experimental hair-growth drug ABS-201 could complement rather than compete with existing treatments citing its infrequent dosing of two to three injections over six months** Renewed investor interest in hair-loss therapies follows Nektar Therapeutics' NKTR.O update last week that its experimental injection stimulated hair regrowth in patients with alopecia areata, a patchy hair-loss condit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nL4N41A1KB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4121","MANE","ABSI","BK4007","NKTR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624600532","title":"Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624600532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624600532?lang=en_us&edition=fundamental","pubTime":"2026-04-01 03:30","pubTimestamp":1774985408,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbSci (ABSI) and RenovoRx (RNXT) with bullish sentim...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-absci-absi-and-renovorx-rnxt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-absci-absi-and-renovorx-rnxt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XLV","BK4139","LU0029874061.USD","LU0128526141.USD","XBI","BK4588","BK4539","RNXT","BK4121","BK4137","LABU","BK4581","HCSG","ABSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311622","title":"Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and MaxCyte (MXCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623311622?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:02","pubTimestamp":1774868523,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-absci-absi-and-maxcyte-mxct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-absci-absi-and-maxcyte-mxct-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","BK4585","LU0029874061.USD","BK4139","XBI","BK4588","LU0128526141.USD","MLTX","XLV","BK4137","BK4581","HCSG","BK4539","MXCT","ABSI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623199463","title":"Absci Price Target Maintained With a $7.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2623199463","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623199463?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:42","pubTimestamp":1774867320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABSI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 06:42 ET (10:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4539","ABSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622071801","title":"Absci Shares Fall 4.9% After Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622071801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622071801?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:31","pubTimestamp":1774445514,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4N40D1AF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABSI","BK4121","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622507073","title":"Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2622507073","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622507073?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:02","pubTimestamp":1774440120,"startTime":"0","endTime":"0","summary":"U.S. stock futures rise, Absci falls pre-market on worse-than-expected sales. Other stocks declining in pre-market trading.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/25/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/25/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51453066/absci-digitalocean-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51453066/absci-digitalocean-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4539","BK4121","ABSI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622078915","title":"Absci price target lowered to $4.20 from $4.32 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078915","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078915?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:35","pubTimestamp":1774438546,"startTime":"0","endTime":"0","summary":"Morgan Stanley lowered the firm’s price target on Absci (ABSI) to $4.20 from $4.32 and keeps an Equal Weight rating on the shares after the company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/absci-price-target-lowered-to-4-20-from-4-32-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/absci-price-target-lowered-to-4-20-from-4-32-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2111349929.HKD","LU1791710400.SGD","LU0006306889.USD","BK4588","LU0528227936.USD","IE00BZ1G4Q59.USD","LU1244550494.USD","LU1668664300.SGD","BK4516","LU2357305700.SGD","BK4585","LU0106831901.USD","BK4139","BK4127","LU1720051017.SGD","LU2347655156.SGD","LU0267386448.USD","LU2089283258.USD","IE00BKVL7J92.USD","LU1791710582.SGD","ABSI","LU0882574139.USD","LU0912757837.SGD","LU1989772840.SGD","LU0158827948.USD","LU1074936037.SGD","LU2028103732.USD","LU0557290698.USD","LU1548497426.USD","BK4539","LU0234570918.USD","BK4121","LU0971096721.USD","LU2023251221.USD","LU0106261372.USD","LU1732799900.SGD","LU0314104364.USD","LU2089284900.SGD","BK4534","LU0158827781.USD","LU2133065610.SGD","LU2271345857.HKD","LU1162221912.USD","LU1989772923.USD","LU1244550577.SGD","LU1363072403.SGD","LU0795875169.SGD","BK4504","LU0320765646.SGD","LU0225283273.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.absci.com;investors.absci.com","stockEarnings":[{"period":"1week","weight":0.0285},{"period":"1month","weight":0.9396},{"period":"3month","weight":1.1894},{"period":"6month","weight":0.7},{"period":"1year","weight":1.1018},{"period":"ytd","weight":0.6562}],"compareEarnings":[{"period":"1week","weight":0.0297},{"period":"1month","weight":0.0881},{"period":"3month","weight":0.0682},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.31},{"period":"ytd","weight":0.0841}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.106318},{"month":2,"riseRate":0.6,"avgChangeRate":0.064917},{"month":3,"riseRate":0.4,"avgChangeRate":-0.085447},{"month":4,"riseRate":0.4,"avgChangeRate":0.03426},{"month":5,"riseRate":0.4,"avgChangeRate":-0.005964},{"month":6,"riseRate":0,"avgChangeRate":-0.147252},{"month":7,"riseRate":0.75,"avgChangeRate":0.242017},{"month":8,"riseRate":0.2,"avgChangeRate":-0.131623},{"month":9,"riseRate":0.2,"avgChangeRate":-0.114873},{"month":10,"riseRate":0.8,"avgChangeRate":0.133791},{"month":11,"riseRate":0.2,"avgChangeRate":-0.134033},{"month":12,"riseRate":0.4,"avgChangeRate":0.218437}],"exchange":"NASDAQ","name":"Absci Corporation.","nameEN":"Absci Corporation."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Absci Corporation.(ABSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Absci Corporation.(ABSI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Absci Corporation.,ABSI,Absci Corporation.股票,Absci Corporation.股票老虎,Absci Corporation.股票老虎国际,Absci Corporation.行情,Absci Corporation.股票行情,Absci Corporation.股价,Absci Corporation.股市,Absci Corporation.股票价格,Absci Corporation.股票交易,Absci Corporation.股票购买,Absci Corporation.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Absci Corporation.(ABSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Absci Corporation.(ABSI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}